NCT01839045

Brief Summary

The major purpose of this study is to evaluate a laboratory developed test that measures multiple breast cancer-specific biomarker proteins in your blood samples. The biomarker results along with your personal medical profile will be evaluated to determine your risk for the presence of a malignancy in the breast as compared to your breast evaluation assessment conducted by your physician.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2013

Geographic Reach
1 country

8 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 5, 2013

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 24, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
Last Updated

June 9, 2014

Status Verified

June 1, 2014

Enrollment Period

1.3 years

First QC Date

April 5, 2013

Last Update Submit

June 6, 2014

Conditions

Keywords

WomanBreast CancerCancerMammogramUltrasoundImagingBiomarkersACR BI RAD Category 3ACR BI RAD Category 4

Outcome Measures

Primary Outcomes (2)

  • Training

    Part I: Establish an acceptable algorithm for generation of a single numerical score from the combination of the 5 cancer biomarkers that comprise the dtectDX-Breast Assay Part II: Define a numerical score cutoff that differentiates malignant from nonmalignant breast cancer in this population of woman.

    Baseline

  • Blinded Validation

    Demonstrate proof-of-concept for use of the dtectDx-Breast Assay to assess likelihood of breast cancer malignancy in conjunction with the physicians clinical and radiological evaluations.

    6 months

Secondary Outcomes (1)

  • Clinical Sensitivity/Specificity

    Baseline

Study Arms (1)

Breast Cancer

ACR BI-RAD Category 3 or 4 result

Eligibility Criteria

Age25 Years - 49 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Primary Care Clinics

You may qualify if:

  • Adult women from 25 years of age to below 50 years of age
  • Breast evaluation results of ACR BI-RADS® Category 3 or 4 by imaging and physicians clinical and radiological evaluation
  • Study visit and blood collection within 3 weeks (21 days) of ACR BI-RADS assessment
  • Patient agrees to return for diagnostic follow-up and blood collection at 6 months unless a positive cancer diagnosis is made between study visits 1 and 2. Individuals diagnosed with LCIS and DCIS will agree to return for visit 2
  • Samples collected under IRB approval and Informed Consent
  • Testing performed under IRB approval or waiver (as applicable)

You may not qualify if:

  • Adults from 50 years of age or older and below 25 years of age
  • Final breast evaluation results other than a ACR BI-RADS Category 3 or 4
  • Subjects that have had a breast biopsy performed at any time prior to the study visit
  • Samples not collected under IRB approval and Informed Consent
  • Testing not performed under IRB approval or waiver (as applicable)
  • Prior breast cancer diagnosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Banner Health

Phoenix, Arizona, 85006, United States

Location

Sutter Institute

Sacramento, California, 95816, United States

Location

Scripps

San Diego, California, 92103, United States

Location

Sansum Clinic

Santa Barbara, California, 93102-1200, United States

Location

Lahey Clinic

Peabody, Massachusetts, 01960, United States

Location

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Location

Rhode Island Hospital

Providence, Rhode Island, 02903, United States

Location

Avera Research Institute

Sioux Falls, South Dakota, 57105, United States

Location

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

At each visit, 35mL or 2 1/2 tablespoons of blood will be drawn from your arm.

MeSH Terms

Conditions

Breast NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2013

First Posted

April 24, 2013

Study Start

March 1, 2013

Primary Completion

June 1, 2014

Study Completion

August 1, 2014

Last Updated

June 9, 2014

Record last verified: 2014-06

Locations